Last reviewed · How we verify
SARS-CoV-2 omicron virus dose arm 1
SARS-CoV-2 omicron virus dose arm 1 is a Biologic drug developed by Hvivo. It is currently in Phase 1 development.
At a glance
| Generic name | SARS-CoV-2 omicron virus dose arm 1 |
|---|---|
| Sponsor | Hvivo |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) (EARLY_PHASE1)
- ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 omicron virus dose arm 1 CI brief — competitive landscape report
- SARS-CoV-2 omicron virus dose arm 1 updates RSS · CI watch RSS
- Hvivo portfolio CI
Frequently asked questions about SARS-CoV-2 omicron virus dose arm 1
What is SARS-CoV-2 omicron virus dose arm 1?
SARS-CoV-2 omicron virus dose arm 1 is a Biologic drug developed by Hvivo.
Who makes SARS-CoV-2 omicron virus dose arm 1?
SARS-CoV-2 omicron virus dose arm 1 is developed by Hvivo (see full Hvivo pipeline at /company/hvivo).
What development phase is SARS-CoV-2 omicron virus dose arm 1 in?
SARS-CoV-2 omicron virus dose arm 1 is in Phase 1.
Related
- Manufacturer: Hvivo — full pipeline
- Compare: SARS-CoV-2 omicron virus dose arm 1 vs similar drugs
- Pricing: SARS-CoV-2 omicron virus dose arm 1 cost, discount & access